Mga Batayang Estadistika
| CIK | 1788028 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amplitude Healthcare Acquisition Corp - Class A
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THE |
|
| August 13, 2025 |
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., August 13, 2025 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spo |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 9, 2025 |
Exhibit 99.1 Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 9, 2025 (GLOBE NEWSWIRE) – Jasper Th |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 7, 2025 |
Exhibit 99.1 Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria 8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W and the 240mg followed by |
|
| July 7, 2025 |
Exhibit 99.2 Jasper Therapeutics Corporate presentation July 2025 2 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statem ents. All statements other than statements of historical fact contained i |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2025 |
Exhibit 99.1 Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No |
|
| June 16, 2025 |
Exhibit 99.2 Jasper Therapeutics SPOTLIGHT Data Update June 16, 2025 2 B RIQU ILIMAB IS AN INVES TIGATIVE DRU G AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements Certain statements in this Presentation include “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than stat |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 12, 2025 |
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Exhibit 99.1 Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven diseases such as chronic spontaneous urtic |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER TH |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 26, 2025 |
Jasper Therapeutics, Inc. Up to $100,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-285914 PROSPECTUS Jasper Therapeutics, Inc. Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, dated March 19, 2025 (the “Sales Agreement”), with Jefferies LLC (“Jefferies”), relating to the sale of shares of our voting common stock, par value $0.0001 per share (“Common Stock”), offered by this prospectus. In |
|
| March 24, 2025 |
Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 March 24, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Tim Buchmiller Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed March 19, 2025 File No. 333-285914 Ladies and G |
|
| March 19, 2025 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM March 19, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through or to Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
|
| March 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Jasper Therapeutics, Inc. |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 19, 2025 |
Exhibit 4.3 Jasper Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 28, 2025 |
Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy. Exhibit 10.17 JASPER Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation d |
|
| February 28, 2025 |
Jasper Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 Jasper Therapeutics, Inc. Insider Trading Policy Section 1. All Employees, Officers, Directors and their Family Members and Affiliates Are Subject to this Policy. This Insider Trading Policy (“Policy”) applies to all employees, directors, officers and consultants (each a “Covered Party”) of Jasper Therapeutics, Inc., a Delaware corporation (“Jasper” or the “Company”), their family mem |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THERAPE |
|
| February 27, 2025 |
Exhibit 99.1 Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., February 27, 2025 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases suc |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 8, 2025 |
Exhibit 99.1 Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of |
|
| January 8, 2025 |
Exhibit 99.2 1 Briquilimab is an investigative drug and is not approved for any indication Jasper Therapeutics: Preliminary BEACON Results NASDAQ: JSPR January 8 th , 2025 2 Briquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2025 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga2soleus3jas.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871202 (CUSIP Number) September 30, 2024 (Date of Event Which |
|
| November 14, 2024 |
JSPR / Jasper Therapeutics, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1153024413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 7, 2024 |
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., November 7, 2024 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spo |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPE |
|
| November 4, 2024 |
JSPR / Jasper Therapeutics, Inc. / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment SC 13G/A 1 zk2432215.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No.2)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| October 15, 2024 |
Exhibit 99.1 Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria 14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, includin |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THE |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 20, 2024 |
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors Exhibit 99.1 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) –Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneo |
|
| June 12, 2024 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of June 10, 2024 by and between Jasper Therapeutics, Inc., a Delaware corporation (the “Corporation”), and Ronald Martell (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 12, 2024 |
Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Executive Leadership Team) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of June 10, 2024 by and between Jasper Therapeutics, Inc., a Delaware corporation (the “Corporation”), and Edwin Tucker, M.D. (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, |
|
| June 12, 2024 |
Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Executive Leadership Team) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of June 10, 2024 by and between Jasper Therapeutics, Inc., a Delaware corporation (the “Corporation”), and Herb Cross (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, underst |
|
| June 12, 2024 |
Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Executive Leadership Team) THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of June 10, 2024 by and between Jasper Therapeutics, Inc., a Delaware corporation (the “Corporation”), and Jeet Mahal (the “Executive”). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, underst |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
Exhibit 4.6 Jasper Therapeutics, Inc. Restricted Stock Award Grant Notice (2024 Equity Incentive Plan) Jasper Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of shares of Common Stock on the terms set forth below in consideration of your services (the “Restricted Stock”). The grant of the Restricted Stock (the “Restricted Stock Award”) is subject to all of the |
|
| June 7, 2024 |
Exhibit 4.5 Jasper Therapeutics, Inc. RSU Award Grant Notice (2024 Equity Incentive Plan) Jasper Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Comp |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
As filed with the Securities and Exchange Commission on June 7, 2024 As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. |
|
| June 7, 2024 |
Jasper Therapeutics, Inc. 2024 Equity Incentive Plan. Exhibit 4.3 Jasper Therapeutics, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: April 19 2024 Approved by the Stockholders: June 6, 2024 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company an |
|
| June 7, 2024 |
Form of Stock Option Award Agreement under the Jasper Therapeutics, Inc. 2024 Equity Incentive Plan. Exhibit 4.4 Jasper Therapeutics, Inc. Stock Option Grant Notice (2024 Equity Incentive Plan) Jasper Therapeutics, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein an |
|
| June 7, 2024 |
Jasper Therapeutics, Inc. 2024 Employee Stock Purchase Plan. Exhibit 4.7 Jasper Therapeutics, Inc. 2024 Employee Stock Purchase Plan Adopted by the Board Of Directors: April 19, 2024 Approved by the Stockholders: June 6, 2024 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a seri |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER TH |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––––––– SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| March 27, 2024 |
JSPR / Jasper Therapeutics, Inc. / Avidity Partners Management LP Passive Investment SC 13G 1 d1100643913g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871202 (CUSIP Number) March 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| March 5, 2024 |
Offer Letter, dated September 19, 2023, by and between Jasper Therapeutics, Inc. and Herb Cross. Exhibit 10.36 September 15, 2023 Herb Cross [. . .***. . .] Dear Name On behalf of Jasper Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position: I am pleased to offer you the position of Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) and Corporate Secretary with the Compan |
|
| March 5, 2024 |
Jasper Therapeutics, Inc. Clawback Policy Exhibit 97 Jasper Therapeutics, Inc. Clawback Policy The Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this Clawback Policy (this “Policy”), which provides for the recovery of certain incentive compensation in the event of an Accounting Restatement (as defined below). This Policy |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 5, 2024 As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. |
|
| March 5, 2024 |
Offer Letter, dated June 7, 2023, by and between Jasper Therapeutics, Inc. and Edwin Tucker. Exhibit 10.35 June 7, 2023 Ed Tucker [. . .***. . .] Dear Ed On behalf of Jasper Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position: I am pleased to offer you the position of Chief Medical Officer with the Company. You will report to Ron Martell, CEO & President. This is a full-time position, and you will be |
|
| March 5, 2024 |
Exhibit 4.3 DESCRIPTION OF SECURITIES OF JASPER THERAPEUTICS, INC. The following summary of certain provisions of the securities of Jasper Therapeutics, Inc. (the “Company”) does not purport to be complete and is subject to the Company’s Second Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), the Company’s Third Amended and Restated Bylaws (the “B |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THERAPE |
|
| March 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| March 4, 2024 |
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments Exhibit 99.1 Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments REDWOOD CITY, Calif., March 4, 2024 – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible |
|
| March 4, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2024 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2024 |
US4718711033 / JASPER THERAPEUTICS INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245287d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (the |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga107422jspr02142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, pa |
|
| February 14, 2024 |
EX-99.1 2 tm245867d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Voting Common Stock par |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) JASPER THERAPEUTICS, InC. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871 202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 12, 2024 |
EX-99.4 Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Erica Herberg, Anat Holt |
|
| February 12, 2024 |
US4718711033 / JASPER THERAPEUTICS INC / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A 1 d661434dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Sui |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871202 (CUSIP Number) Ada |
|
| February 7, 2024 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-271500 PROSPECTUS SUPPLEMENT Dated February 6, 2024 (To prospectus dated May 5, 2023) 3,900,000 Shares Common Stock We are offering 3,900,000 shares of our voting common stock, par value $0.0001 per share (“Common Stock”). Our Common Stock is listed for trading on the Nasdaq Capital Market under the symbol “JSPR.” On February 5, 2024, the last |
|
| February 6, 2024 |
Exhibit 1.1 3,900,000 Shares of Common Stock Jasper Therapeutics, Inc. UNDERWRITING AGREEMENT February 6, 2024 Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street, 35th Floor New York, New York 10055 Dear Sirs: 1. Introductory. Jasper Therap |
|
| February 6, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 6, 2024 |
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock Exhibit 99.1 Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock REDWOOD CITY, Calif., February 6, 2024 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower t |
|
| February 5, 2024 |
US4718711033 / JASPER THERAPEUTICS INC / SPHERA FUNDS MANAGEMENT LTD. - SC 13G/A Passive Investment SC 13G/A 1 zk2430880.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No.1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 2, 2024 |
SC 13G/A 1 ea192414-13ga1soleusjasper.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 471871202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State |
|
| January 4, 2024 |
Exhibit 3.1 Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “JASPER THERAPEUTICS, INC.”, FILED IN THIS OFFICE ON THE THIRD DAY OF JANUARY, A.D. 2024, AT 1:29 O’CLOCK P.M. 7559945 8100 SR# 20240019851 Authentication: 202516338 Date: 01-03-24 You may verify |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 2, 2024 |
Jasper Therapeutics, Inc. Announces Reverse Stock Split Exhibit 99.1 Jasper Therapeutics, Inc. Announces Reverse Stock Split REDWOOD CITY, Calif., Jan. 2, 2024 - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2024 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 20, 2023 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ––––––––––––––––––––––––––––––––––––––––––– SCHEDULE 14A INFORMATION (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2023 |
PRELIMINARY COPY DATED NOVEMBER 9, 2023 — SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2023 |
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 9, 2023 – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic indu |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 1, 2023 |
Exhibit 99.1 Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors REDWOOD CITY, Calif., November 1, 2023 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spont |
|
| October 20, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commiss |
|
| October 10, 2023 |
Joint Filing Agreement by and among the Reporting Persons EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Jasper Therapeutics, Inc.; each of them is responsible for the |
|
| October 10, 2023 |
Exhibit 99.1 Briquilimab is an investigative drug and is not approved for any indication 1 Jasper Therapeutics NASDAQ: JSPR October 2023 Exhibit 99.1 2 Briquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - look |
|
| October 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 10, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / SPHERA FUNDS MANAGEMENT LTD. - SC 13G Passive Investment SC 13G 1 zk2330364.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) September 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| October 10, 2023 |
Exhibit 99.1 Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024 REDWOOD CITY, Calif., October 9, 2023 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSP |
|
| October 10, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 25, 2023 |
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer Jeet Mahal Continues as COO Exhibit 99.1 Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer Jeet Mahal Continues as COO REDWOOD CITY, Calif., September 25, 2023 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), |
|
| September 21, 2023 |
Exhibit 99.1 Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium ● All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recovery ● Briquilimab was well tolerated without any complications ● Study expansion to Phase 2a is o |
|
| September 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| August 11, 2023 |
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update ● First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome ● Strengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., August 11, 2023 – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology compa |
|
| August 11, 2023 |
Exhibit 10.2 *** Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets (“[...***...]”) in this exhibit. *** S06-265: DXL Amendment 7/27/2023 AMENDMENT № 1 TO THE EXCLUSIVE LICENSE AGREEMENT EFFECTIVE THE 25th DAY OF |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THER |
|
| June 20, 2023 |
Exhibit 99.1 Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnolo |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 8, 2023 |
Jasper Therapeutics, Inc. 2022 Amended and Restated Inducement Equity Incentive Plan. Exhibit 10.1 JASPER THERAPEUTICS, INC. AMENDED AND RESTATED 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permit |
|
| June 8, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JASPER THERAPEUTICS, INC. Jasper Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the Corporation is Jasper Therapeutics, Inc. The Corporation was originally incorporated under the name “Amplitude |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2023 |
Exhibit 99.1 Harnessing the Power of Jasper’s Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR June 2023 Safe Harbor Statements Briquilimab is an investigative drug and is not approved for any indication 2 Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All statements other |
|
| May 12, 2023 |
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Exhibit 99.1 Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update ● Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous Urticaria ● Presented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTC |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THE |
|
| May 5, 2023 |
Jasper Therapeutics, Inc. Up to $75,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-271500 PROSPECTUS Jasper Therapeutics, Inc. Up to $75,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, dated November 10, 2022 (the “Sales Agreement”), with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), relating to shares of our voting common stock, par value $0.0001 per share (“Common Stock”), offered |
|
| May 3, 2023 |
Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 May 3, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Jason Drory Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed April 28, 2023 File No. 333-271500 Ladies and Gentlem |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Jasper Therapeutics, Inc. |
|
| April 28, 2023 |
Exhibit 4.3 Jasper Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establi |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2023 |
Exhibit 10.1 April 13, 2023 William Lis Delivered via email: [email protected] Re: Service Agreement - Chairperson of the Board and Consulting Services Dear Bill: Reference is made to that certain Service Agreement, dated March 7, 2022 (the “Service Agreement”), by and between William Lis (“Lis”) and Jasper Therapeutics, Inc., a Delaware corporation (the “Company” and, together with Lis, |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commissio |
|
| April 14, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into on April 13, 2023, by and between Jasper Therapeutics, Inc. (the “Company”) and Ronald Martell (the “Executive”). RECITALS: WHEREAS, the Company and the Executive are parties to that certain Employment Agreement made and entered into as of February 25, 2022, |
|
| April 10, 2023 |
PRELIMINARY COPY DATED APRIL 10, 2023 – SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THERAPE |
|
| March 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2023 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2023 |
Exhibit 4.3 DESCRIPTION OF SECURITIES OF JASPER THERAPEUTICS, INC. The following summary of certain provisions of the securities of Jasper Therapeutics, Inc. (the “Company”) does not purport to be complete and is subject to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), the Company’s Second Amended and Restated Bylaws (the “Bylaws”) and |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 As filed with the Securities and Exchange Commission on March 8, 2023 Registration No. |
|
| March 8, 2023 |
Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy. Exhibit 10.17 JASPER Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation d |
|
| March 8, 2023 |
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update Exhibit 99.1 Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business Update ● Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous Urticaria ● Presentation of Key Briquilimab Clinical Data, Including Initial Results in Stem Cell Transplant for Sickle Cell Disease and One Year Follow-Up for Acute Myeloid Leukemia |
|
| February 27, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Voting Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., a Delaware corporat |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) Adam |
|
| February 17, 2023 |
Exhibit 99.1 Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR ● Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning w |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 17, 2023 |
Third Amended and Restated Bylaws of the Registrant. Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF JASPER THERAPEUTICS, INC. Article I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corp |
|
| February 17, 2023 |
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors Exhibit 99.2 Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors REDWOOD CITY, Calif., February 17, 2023 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelody |
|
| February 16, 2023 |
Exhibit 99.1 Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients Data Presented in Plenary Session at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR ● First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up ● |
|
| February 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm234574d41sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Jasper Therapeutics, Inc. (Name of Issuer) Voting common stock, par value $0.0001 per share (the |
|
| February 13, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / ROCHE FINANCE LTD - SC 13G/A Passive Investment SC 13G/A 1 tm236317d2sc13ga.htm SC 13G/A CUSIP No. 471871 103 SCHEDULE 13G/A Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 - Exit Filing)* JASPER THERAPEUTICS, INC. (Name of Issuer) Voting Common Stock, par value, $0.0001 per share (Title of Class of Securities) 471871 103 (CUSIP Number) D |
|
| February 10, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / AMGEN INC - SC 13G/A Passive Investment SC 13G/A 1 d447460dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 471871 103 (CUSIP Number) January 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP |
|
| February 6, 2023 |
EX-99.1 2 ex991to13g07422jspr02062023.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 6, 2023 with respect to the Voting Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be |
|
| January 31, 2023 |
US4718711033 / JASPER THERAPEUTICS INC / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. |
|
| January 30, 2023 |
EX-99.A 2 d436174dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement i |
|
| January 30, 2023 |
SC 13G 1 d436174dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 471871 103 (CUSIP Number) January 27, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 27, 2023 |
EX-99.1 2 ea172298ex99-1jasper.htm PRESS RELEASE, DATED JANUARY 27, 2023 Exhibit 99.1 Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares REDWOOD CITY, Calif., January 27, 2023 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibo |
|
| January 27, 2023 |
EX-99.1 2 ex991to13ga112927jspr012723.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 27, 2023 with respect to the Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersig |
|
| January 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 27, 2023 |
SC 13G/A 1 sc13ga112927jspr01272023.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Jasper Therapeutics, Inc. (Name of Issuer) Common Stock, par v |
|
| January 25, 2023 |
Exhibit 1.1 JASPER THERAPEUTICS, INC. 60,000,000 Shares of Common Stock, par value $0.0001 per share UNDERWRITING AGREEMENT January 25, 2023 Credit Suisse Securities (USA) LLC William Blair & Company, L.L.C. Oppenheimer & Co. Inc. As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue New York, New York 10010-3629 c/o William Blair & Company, |
|
| January 25, 2023 |
Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock Exhibit 99.1 Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock REDWOOD CITY, Calif., January 25, 2023 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelody |
|
| January 25, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 25, 2023 |
60,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-267777 PROSPECTUS SUPPLEMENT (to Prospectus dated October 18, 2022) 60,000,000 Shares of Common Stock We are offering 60,000,000 shares of our voting common stock, par value $0.0001 per share (“Common Stock”), in this offering. Our Common Stock is listed on the Nasdaq Capital Market under the symbol “JSPR.” On January 23, 2023, the closing pric |
|
| January 24, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 24, 2023 |
Subject to Completion, Dated JANUARY 24, 2023 Filed pursuant to Rule 424(b)(5) Registration No. 333-267777 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| January 24, 2023 |
Exhibit 99.1 Harnessing the Power of Jasper’s Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR January 2023 Exhibit 99.1 2 Briquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All |
|
| January 19, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 13, 2023 |
EX-99.1 2 ea171626ex99-1jasper.htm PRESS RELEASE, DATED JANUARY 13, 2023 Exhibit 99.1 Jasper Therapeutics Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Three abstracts highlight the safety and efficacy of briquilimab combined with low-toxicity radiation conditioning to achieve full donor engraftm |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 10, 2023 |
Exhibit 99.2 Harnessing the Power of Jasper’s Differentiated c - Kit Therapeutic Approach Nasdaq: JSPR January 2023 Exhibit 99.2 2 Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All statements other than statements of historical fact contained in this Presen |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2023 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 10, 2023 |
Exhibit 99.1 Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases REDWOOD CITY, Calif., January 10, 2023 - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies and stem c |
|
| November 10, 2022 |
Up to $15,500,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-267777 PROSPECTUS SUPPLEMENT (to Prospectus dated October 18, 2022) Up to $15,500,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, dated November 10, 2022 (the ?Sales Agreement?), with Cantor Fitzgerald & Co. (?Cantor Fitzgerald?), relating to shares of our voting common stock, par value $0.0001 per share (? |
|
| November 10, 2022 |
Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia Patients - Fast Track Designation Granted to JSP191 for Treatment of Patients with Severe Combined Immunodeficiency (SC |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2022 |
Exhibit 10.1 Jasper Therapeutics, Inc. Shares of Voting Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement November 10, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Jasper Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as f |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER |
|
| November 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commiss |
|
| October 18, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-260306 Prospectus Jasper Therapeutics, Inc. 31,019,499 Shares of Voting Common Stock Up to 4,999,863 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus relates to: (i) the resale by the investors listed in the section of this prospectus entitled ?Selling Stockholders? (the ?Selling Stockholders?) of up to 31,019,49 |
|
| October 14, 2022 |
Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 Jasper Therapeutics, Inc. 2200 Bridge Pkwy, Suite # 102 Redwood City, CA 94065 October 14, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attention: Jimmy McNamara Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed October 7, 2022 File No. 333-267777 Ladies an |
|
| October 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Jasper Therapeutics, Inc. |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022. As filed with the Securities and Exchange Commission on October 7, 2022. Registration No. 333-260306 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jasper Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-2984849 (State or other |
|
| October 7, 2022 |
Exhibit 4.3 Jasper Therapeutics, Inc. INDENTURE Dated as of [ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establi |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 As filed with the Securities and Exchange Commission on October 7, 2022 Registration No. |
|
| August 12, 2022 |
Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia - On schedule to initiate a registrational study in AML in the first quarter of 2023 - On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lower-risk, tr |
|
| August 12, 2022 |
PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to Prospectus dated March 29, 2022) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 4,999,883 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus supplement supplements the prospectus, dated March 29, 2022 (the ?Prospectus?), which forms a part of our regi |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction (Commission File Number) (I |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THER |
|
| August 11, 2022 |
US4718711033 / JASPER THERAPEUTICS INC / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (N |
|
| August 11, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| August 11, 2022 |
Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to Prospectus dated March 29, 2022) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 4,999,883 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus supplement supplements the prospectus, dated March 29, 2022 (the ?Prospectus?), which forms a part of our regi |
|
| May 12, 2022 |
Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update Exhibit 99.1 Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update - Successful meeting with the FDA; the Company intends to initiate registrational studies in MDS and AML in Q1-2023 - Clinical data from the Phase 1 study of JSP191 as a conditioning regimen in patients with MDS or AML presented at the 2022 Transplantation & Cellular Therapy (TCT) Annual M |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER THE |
|
| May 12, 2022 |
Exhibit 10.6 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS In order to settle as fully as possible all known and unknown claims that I, Kevin Heller (?I,? ?me,? ?my?), might have against Jasper Therapeutics, Inc. (the ?Company?), and all related parties, the Company and I agree to the terms and conditions of this Confidential Separation Agreement and General Release of All Cl |
|
| April 29, 2022 |
DEFA14A 1 ea158747-defa14ajasper.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
SC 13G/A 1 ea158994-13ga1amplijasper.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 471871 103 (CUSIP Number) April 12, 2022 (Date of Event Whi |
|
| April 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 27, 2022 |
Exhibit 99.1 |
|
| April 1, 2022 |
424B3 1 f424b30322jaspertherap.htm PROSPECTUS Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 4,999,883 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus relates to: (i) the resale by the investors listed in the section of this prospectus entitled “Selling Stockholders” ( |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022. As filed with the Securities and Exchange Commission on March 24, 2022. Registration No. 333-260306 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jasper Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 2836 84-2984849 (State or other jurisdi |
|
| March 22, 2022 |
As filed with the Securities and Exchange Commission on March 22, 2022 As filed with the Securities and Exchange Commission on March 22, 2022 Registration No. |
|
| March 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 21, 2022 |
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team Exhibit 99.1 Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team REDWOOD CITY, Calif., March 21, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced changes to its management team, including the promotions of Jeet Mahal to the newly created position of Chief Operating Officer, and of |
|
| March 18, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES OF JASPER THERAPEUTICS, INC. The following summary of certain provisions of the securities of Jasper Therapeutics, Inc. (the ?Company?) does not purport to be complete and is subject to the Company?s Second Amended and Restated Certificate of Incorporation (the ?Certificate of Incorporation?), the Company?s Second Amended and Restated Bylaws (the ?Bylaws?) and |
|
| March 18, 2022 |
Exhibit 10.7 JASPER THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Unless otherwise defined herein, the terms defined in the Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Unit Agreement (the ?Award Agreement?), which includes the Notice of Restricted Stock Unit Gran |
|
| March 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 18, 2022 |
Exhibit 10.6 JASPER THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Stock Option Agreement (the ?Agreement?), including the Notice of Stock Option Grant (the ?Notice of Grant?) and Terms an |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39138 JASPER THERAPE |
|
| March 18, 2022 |
Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update Exhibit 99.1 Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update REDWOOD CITY, Calif., March 18, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update. Highlights for Recen |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Jasper Therapeutics, Inc. |
|
| March 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 16, 2022 |
Jasper Therapeutics, Inc. 2022 Inducement Equity Incentive Plan. Exhibit 10.1 JASPER THERAPEUTICS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonsta |
|
| March 16, 2022 |
Exhibit 99.1 Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022 2 JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this ?Presentation?) contain forward - looking statements . All statements other than statements of hi |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 11, 2022 |
Service Agreement, dated March 7, 2022, by and between Jasper Therapeutics, Inc. and William Lis. Exhibit 10.1 March 7, 2022 William Lis Delivered via email Re: Service Agreement - Chairperson of the Board and Consulting Services Dear Bill: On behalf of Jasper Therapeutics, Inc., a Delaware corporation (the ?Company?), I am pleased to present an offer on the following terms regarding your continued service to the Company as Chairperson of the Company?s Board of Directors (the ?Board?) and foll |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2022 JASPER THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39138 84-2984849 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 28, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of February 25, 2022 by and between Jasper Therapeutics, Inc., a Delaware corporation (the ?Corporation?), and Ronald Martell (the ?Executive?). RECITALS THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions: A. The Corporation desires that the Ex |
|
| February 28, 2022 |
Exhibit 99.1 Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer - William Lis to Continue as Chairman, Board of Directors - REDWOOD CITY, CA; February 28, 2022 - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Ronald Martell as the company?s Chief Executive O |
|
| February 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2022 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commis |
|
| February 25, 2022 |
Exhibit 99.1 Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR ? JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in Ph1b dose expansion study ? 17 of 17 subjects achieved su |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Jasper Therapeutics, Inc. (Name of Issuer) Voting common stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 4 |
|
| February 14, 2022 |
US4718711033 / JASPER THERAPEUTICS INC / UBS OCONNOR LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Jasper Therapeutics , Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 11, 2022 |
US4718711033 / JASPER THERAPEUTICS INC / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jasper Therapeutics, Inc. (f/k/a Amplitude Healthcare Acquisition Corporation) (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 471871103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Stateme |
|
| February 3, 2022 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Voting Common Stock, par value $0. |
|
| February 3, 2022 |
US4718711033 / JASPER THERAPEUTICS INC / TENOR CAPITAL MANAGEMENT Co., L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39138 JASPER |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2021 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commis |
|
| November 12, 2021 |
Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 12, 2021 - Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for the quarter ended September 30, 2021, and provided a business update. Highlights of the quarter and rec |
|
| November 12, 2021 |
424B3 1 ea150462-424b3jaspertherap.htm PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to Prospectus dated October 26, 2021) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 5,000,000 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus supplement supplements the prospectus, dated Oc |
|
| October 29, 2021 |
Jasper Therapeutics, Inc. Non-Employee Director Compensation Policy. Exhibit 10.1 JASPER Therapeutics, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each non-employee member of the board of directors (the ?Board?) of Jasper Therapeutics, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation for his or her service on the Board as set forth in this Non-Employee Director Compensation Policy (this ?Policy?). The cash and equity compensation de |
|
| October 29, 2021 |
PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to Prospectus dated October 26, 2021) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 5,000,000 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus supplement supplements the prospectus, dated October 26, 2021 (the ?Prospectus?), which forms a part of our |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2021 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39138 84-2984849 (State or other jurisdiction of incorporation) (Commiss |
|
| October 26, 2021 |
Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-260306 Jasper Therapeutics, Inc. 33,081,493 Shares of Voting Common Stock Up to 5,000,000 shares of Voting Common Stock Issuable Upon Exercise of Warrants This prospectus relates to: (i) the resale by the investors listed in the section of this prospectus entitled ?Selling Stockholders? (the ?Selling Stockholders?) of up to 33,081,49 |
|
| October 22, 2021 |
2200 Bridge Parkway Suite #102 Redwood City, CA 94065 CORRESP 1 filename1.htm 2200 Bridge Parkway Suite #102 Redwood City, CA 94065 October 22, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Jasper Therapeutics, Inc. Registration Statement on Form S-1, filed on October 18, 2021 File No. 333-260306 (the “Registration Statement”) Ladies and Gentlemen: In accordance wi |
|
| October 18, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jasper Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 2836 84-2984849 (State or other jurisdiction of incorporation or organization |
|
| October 4, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13G and any future amendments thereto reporting each of the undersigned?s ownership of securities of the Issuer named herein, and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisi |
|
| October 4, 2021 |
Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock of Jasper Therapeutics, Inc. |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* JASPER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 471871 103 (CUSIP Number) September 24, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| October 4, 2021 |
AMHC / Amplitude Healthcare Acquisition Corp / Abingworth LLP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Jasper Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 471871103 (CUSIP Number) John Heard Abingworth LLP Princes House 38 Jermyn Street London, England SW1Y 6DN +44 20 7534 1500 (Name, Address and Telephone Numb |
